263 related articles for article (PubMed ID: 22013048)
21. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
[TBL] [Abstract][Full Text] [Related]
22. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Crook T; Tidy JA; Vousden KH
Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
[TBL] [Abstract][Full Text] [Related]
23. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
Hengstermann A; Linares LK; Ciechanover A; Whitaker NJ; Scheffner M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1218-23. PubMed ID: 11158620
[TBL] [Abstract][Full Text] [Related]
24. Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
Gardiol D; Banks L
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1963-70. PubMed ID: 9714244
[TBL] [Abstract][Full Text] [Related]
25. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
26. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
27. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
28. Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types.
Schütze DM; Snijders PJ; Bosch L; Kramer D; Meijer CJ; Steenbergen RD
J Virol; 2014 Feb; 88(3):1714-24. PubMed ID: 24257607
[TBL] [Abstract][Full Text] [Related]
29. Cellular distribution of tumour suppressor protein p53 and high-risk human papillomavirus (HPV)-18 E6 fusion protein in wild-type p53 cell lines.
Sun L; Zhang G; Li Z; Lei T; Huang C; Song T; Si L
J Int Med Res; 2008; 36(5):1015-21. PubMed ID: 18831896
[TBL] [Abstract][Full Text] [Related]
30. A conserved C-terminal sequence of high-risk cutaneous beta-human papillomavirus E6 proteins alters localization and signalling of β1-integrin to promote cell migration.
Holloway A; Storey A
J Gen Virol; 2014 Jan; 95(Pt 1):123-134. PubMed ID: 24154967
[TBL] [Abstract][Full Text] [Related]
31. Papillomavirus E6 PDZ interactions can be replaced by repression of p53 to promote episomal human papillomavirus genome maintenance.
Brimer N; Vande Pol SB
J Virol; 2014 Mar; 88(5):3027-30. PubMed ID: 24352452
[TBL] [Abstract][Full Text] [Related]
32. Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6.
Lorenz LD; Rivera Cardona J; Lambert PF
PLoS Pathog; 2013 Oct; 9(10):e1003717. PubMed ID: 24204267
[TBL] [Abstract][Full Text] [Related]
33. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells.
Tao M; Kruhlak M; Xia S; Androphy E; Zheng ZM
J Virol; 2003 Dec; 77(24):13232-47. PubMed ID: 14645580
[TBL] [Abstract][Full Text] [Related]
34. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.
von Knebel Doeberitz M; Rittmüller C; Aengeneyndt F; Jansen-Dürr P; Spitkovsky D
J Virol; 1994 May; 68(5):2811-21. PubMed ID: 8151752
[TBL] [Abstract][Full Text] [Related]
35. Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses.
Ainsworth J; Thomas M; Banks L; Coutlee F; Matlashewski G
Virol J; 2008 Jun; 5():67. PubMed ID: 18518978
[TBL] [Abstract][Full Text] [Related]
36. Differential localization of HPV16 E6 splice products with E6-associated protein.
Vaeteewoottacharn K; Chamutpong S; Ponglikitmongkol M; Angeletti PC
Virol J; 2005 Jun; 2():50. PubMed ID: 15960845
[TBL] [Abstract][Full Text] [Related]
37. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
[TBL] [Abstract][Full Text] [Related]
38. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
Scheffner M; Takahashi T; Huibregtse JM; Minna JD; Howley PM
J Virol; 1992 Aug; 66(8):5100-5. PubMed ID: 1321290
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.
Chen AA; Heideman DA; Boon D; Chen Z; Burk RD; De Vuyst H; Gheit T; Snijders PJ; Tommasino M; Franceschi S; Clifford GM
Virology; 2014 Jan; 448():356-62. PubMed ID: 24314666
[TBL] [Abstract][Full Text] [Related]
40. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
